Introduction
In response to various stimuli such as addition of DNA-damaging agents, withdrawal of growth factors, and virus infection, cells undertake a suicide program, known as apoptosis (White, 1996) . The central key molecules controlling this phenomenon are the Bcl-2 family proteins which localize in mitochondria and form complexes with each other through the Bcl-2 homology domain. Bcl-2 and Bcl-XL have an antiapoptotic eect, while Bax and Bad promote apoptosis (Kelakar and Thompson, 1998) . Cell survival or death is determined by the quantitative and/or qualitative state of these two groups of proteins. One of the apoptotic triggers downstream of the Bcl-2 family proteins is an eux of cytochrome c from mitochondria into cytoplasm, which results in the activation of a speci®c group of cystein proteases, the caspases (Alnemri et al., 1996) . Although more than 10 dierent caspases have now been isolated. caspase-9 and -3 are successively activated by the mitochondrial apoptotic signal (Green and Reed, 1998) . Also, caspase-3 may act on terminal eector molecules, such as the caspaseactivated DNase, CAD, which degrades genomic DNA into fragments with a ladder of nucleosomal unit lengths (Enari et al., 1998) and gelsolin, the digestion of which by the caspase destroys the framework of actin ®laments (Kothakota et al., 1997) . Fas ligand/Fas and TNF (tumor necrosis factor)/TNFR (TNF receptor) are also important mediators of apoptosis. When activated, Fas and TNFR activate other members of the caspase group, such as caspase-8 or -10 (Ashkenazi and Dixit, 1998) . This also leads to activation of caspase-3 and the induction of apoptosis. Thus, some apoptotic pathways have been partially elucidated, but many questions remain unresolved.
Although apoptosis is essential for embryogenesis and homeostasis in multicellular organisms, it may also be closely associated with cancer development since alterations of apoptosis-related genes are frequently detected in various cancer cells. Inactivation of the apoptosis-inducing gene, p53, is a common feature of many cancers (Hollstein et al., 1991) . Overexpression of the anti-apoptotic gene, Bcl-2, has been found in B cell follicular lymphoma and other malignancies (Tsujimoto et al., 1984) . Forced expression of another anti-apoptotic gene, Akt, an oncogene ®rst identi®ed in an oncogenic retrovirus, has led to the transformation of cells (Bellacosa et al., 1991) . These alterations render the cells resistant to apoptosis, suggesting that inhibition of apoptosis may be indispensable for cancer development.
In the present study, we report the isolation of a new apoptosis-inducing gene, ASY, from human diploid ®broblasts. Unlike other known apoptosis-inducing genes, the ASY protein targeted the endoplasmic reticulum (ER), and had no homology to other known apoptosis-related motifs. This indicates that ASY is a new type of apoptosis-inducing gene. Further, the ectopic expression of this gene led to extensive apoptosis particularly in cancer cells, and expression of the ASY mRNA was suppressed in small cell lung cancer, suggesting a link between the ASY gene and human cancer. This gene may be very useful in understanding apoptotic mechanisms that have not yet been clari®ed and the relationship between apoptosis and cancer development. It may also be applicable to gene therapy of cancers.
Results

Isolation of the novel gene ASY
During attempts to isolate tumor suppressor genes, we cloned an interesting cDNA, ASY. It is 2054 bp long and contains one open reading frame and a long 3' untranslated region. Nucleotide sequences around the ®rst ATG codon contained Kozak's consensus sequences, and the 5'-race analysis showed the presence of an in-frame stop codon 126 bases upstream from the ®rst ATG codon (data not shown). The putative protein deduced from the nucleotide sequences was composed of 373 amino acids and contained a highly acidic region, a proline-rich region, two hydrophobic domains, a leucine zipper-like motif, and an ER retrieval motif (Jackson et al., 1990) (Figure 1 ). The molecular weight of the ASY gene product was calculated to be 40.3 kD from the sequences, but the FLAG-tagged ASY protein migrated to a position of about 50 kD on the SDS-polyacrylamide gel (see Figure 6b) . Phosphorylation of the FLAG-tagged ASY protein was not detected by immunoprecipitation analysis (data not shown). ASY mRNA was expressed ubiquitously and at almost the same levels in all tissues examined (Figure 2 ). The major transcript was about 2.4 kb in size, but transcripts with dierent sizes (1.8 and 5 kb) were also expressed in certain tissues such as the brain, liver and muscles (Figure 2) . Expression of this gene was independent of cell cycles in normal ®broblasts (data not shown). Southern blot analysis showed that it may be a single copy gene and conserved in various higher vertebrates, such as the monkey, rat, mouse, cow and dog (data not shown). This cDNA has sequence homology with various EST (expressed sequence tag)-clones, but there are no reports of its functional analysis. The C-terminal portion of this cDNA showed a strong homology with a neuroendocrine speci®c protein (NSP) and related reticulon family genes (Roebroek et al., 1993) . NSP mRNA and its protein are expressed only in the brain and certain types of small cell lung cancer (Roebroek et al., 1989) , but their function has not been clari®ed either. Recently, however, a new reticulon family gene, Nogo-A, has been reported to inhibit axonal regeneration in the central nervous system (Chen et al., 2000; GrandPre et al., 2000; Prinjha et al., 2000) . The ASY is identical to a splice variant of the gene, Nogo-B. The chromosome map presented by the National Center for Biotechnology Information suggested that the ASY gene is mapped to human chromosome 2p15-21.
Induction of apoptosis by ASY
To evaluate the function of the ASY gene, we introduced an ASY expression vector, pCASY, into a tumorigenic HeLa-derived cell line, CGL4. Although Figure 3a) . Meanwhile, a control vector, pCNeo, formed a large number of drug-resistant colonies. These results suggest that the ASY gene induces growth arrest or cell death. The inhibition of colony formation by the ASY gene was observed not only in CGL4 but also in other cell lines such as SaOS-2 (see Figure 6c ), indicating that this activity is not speci®c to the CGL4 cell line but is also eective in other cell lines. This activity might be quite powerful, because it was very dicult to obtain stable ASYtransfectants. We examined more than 30 drugresistant CGL4 colonies for expression of the ectopic ASY mRNA but failed to obtain stable ASYexpressing clones. On the other hand, when a nontumorigenic HeLa-derived cell line, CGL1, or an immortalized human ®broblast cell line, HFI, was transfected with the ASY expression vector, more drug-resistant colonies appeared (Figure 3b ,c) and multiple CGL1 clones expressing the ectopic ASY mRNA were obtained (data not shown). This indicates that these non-malignant cell lines are relatively resistant to the ASY gene and that therefore this activity of the ASY gene was not due to the general cytotoxicity of an overexpressed protein.
Additional experiments showed that the ASY gene induced cell death by apoptosis but not by arresting growth. When transfected with the ASY expression vector, SaOS-2 cells exhibited prominent morphological changes characteristic of apoptosis, such as the rounding and shrinking of cells and the appearance of apoptotic bodies (Figure 4a ). These morphological changes occurred very rapidly and the rounded cells could be detected as early as 8 h after transfection. DNA fragmentation and the activation of caspase-3 were also observed after transfection with the ASY cDNA (Figure 4b,d ). Further, we tried to stain apoptotic cells with FITC-labeled annexin V. At very early stages of apoptosis, phosphatidylserine is known to translocate from the inner cell membrane to the cell surface, and the surface phosphatidylserine can be stained with FITC-labeled annexin V, which binds speci®cally to it (Martin et al., 1995) . The number of cells stained with FITC-annexin V increased after transfection with the ASY cDNA ( Figure 4c ). Finally, we demonstrated ASY-induced apoptosis more directly using a GFP (green¯uorescent protein)-tagged ASY expression vector. When SaOS-2 cells were transfected with a control GFP expression vector, many cells emitted green¯uorescence in all areas of the cells. However, when transfected with the GFP-ASY vector, ASY-expressing cells tended to die and exfoliate from the dish, thereby drastically decreasing the number of uorescent cells (Figure 4e ). The¯uorescence that appeared in a small number of positive cells was segregated in the perinuclear region and was mostly segmented (Figure 4e ). Other cancer cell lines were also sensitive to this gene. Figure 4e shows the ecient cell deaths of a melanoma cell line, MeWo, and a ®brosarcoma cell line, HT-1080, when transfected with the GFP ± ASY vector. On the other hand, the nontumorigenic cell line, CGL1, and the immortalized, non-malignant, human ®broblast cell line, HFI, were much more resistant to the ASY gene than the cancer cell lines (Figure 4e and data not shown). These results indicated that, when overexpressed, the ASY gene induced extensive apoptosis particularly in cancer cells.
ASY is a new type of apoptosis-inducing gene
Although the ASY gene was shown to induce apoptosis, it has no homology to any other known apoptosis-related genes or domains. Instead, it has a unique functional motif, a double lysine ER retrieval motif (KK motif) (Jackson et al., 1990) at its Cterminal end (Figure 1) . To examine the localization of the ASY protein, we ®rst performed immuno¯uores-cence analysis after transfection of CGL1(Bcl-2) cells, which overexpress the ectopic Bcl-2 protein, with the FLAG-tagged ASY. As shown in Figure 5a , the FLAG-ASY protein was generally localized in the perinuclear region, suggesting ER localization. Further, we fractionated the transfected cells into mitochondrial, microsomal, and cytosolic components, and then carried out Western blotting. To assess the quality of fractionation, we used two antibodies against Bcl-2, which localizes mainly in mitochondria and partly in other membranous structures, and MAPK (ERK2), which is a cytosol protein, and we showed that both proteins were detected in the components as expected (Figure 5b ). Figure 5b also shows that the majority of the ASY protein was detected in a microsome fragment, the main components of which are microvesicles derived from the ER. These results indicate that ASY protein, like other reticulon family proteins including Nogo-A, targets the ER.
To determine which functional domain of ASY is required for apoptosis, we constructed various mutant 6 cells/ 60 mm dish) were transfected with the ASY cDNA (2 mg), transferred to three 100 mm dishes, and cultured in DMEM containing 300 ± 400 mg/ml G418. The number of colonies was counted 2 weeks after selection. Results are means+s. Figure 6a , and examined their apoptosis-inducing activity. The expression and stability of these mutant proteins were not greatly aected (Figure 6b) . When CGL4 or SaOS-2 cells were transfected, mutants in which the N-terminal or central part, including the acidic or proline-rich region, was deleted retained full apoptotic ability (Figure 6c ), indicating that these regions are not required for apoptosis. Surprisingly, the C-terminal KK motif was not essential for the activity either (Figure 6c ). On the other hand, a mutant in which a TTL (translational termination linker) had been inserted just upstream of the second hydrophobic domain, a mutant in which a region between two hydrophobic domains had been deleted, and a mutant with a substitution in the leucine-zipper like motif lost the ability to induce apoptosis (Figure 6c ). This suggests that the second hydrophobic region, including The lysate was then added to a reaction buer and substrate (DEVD-7-amino-4-tri¯uoromethyl coumarin), incubated at 378C for 1 h, and thē uorescence was measured at 505 nm. Caspase-3 was activated in ASY-transfected cells, and inhibited by treatment with the inhibitor. (e) Cancer cell lines, SaOS-2, HT1080, and MeWo, as well as an immortalized human ®broblast HFI, were transfected with pGFPASY, an expression vector for GFP-fused ASY protein, or pGFP, a control vector. The cells were then ®xed with 4% paraformaldehyde 16 h later and photographed under a¯uorescence microscope. These cancer cell lines underwent apoptosis at a high eciency, whereas the non-malignant cell line HFI was considerably resistant to the ASY gene the leucine-zipper like motif and the adjacent region, are important for apoptosis.
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Considering the results of this study, it is clear that ASY is a new type of apoptosis-inducing gene that targets the ER.
Suppression of ASY transcription in small cell lung cancer
Since it has been suggested that the tumorigenic process may involve the suppression of apoptosis, we attempted to detect alterations of ASY mRNA expression in various cancer cells by mRNA in situ hybridization. As shown in Figure 2 and our unpublished data, ASY mRNA was expressed in all of 61 dierent normal human tissues examined, suggesting ubiquitous expression of this gene. However, ASY transcription was suppressed in ®ve of ®ve small cell lung carcinomas (SCLC) examined (Figure 7e,h ). Positive signals in Figure 7e ,h were due to the in®ltration of lymphocytes in the tumorous region, which served as an internal control of the assay. Normal lung alveolar and bronchial epithelial cells and lung adenocarcinoma and squamous cell carcinoma were also positive ( Figure  7b and data not shown). When an ASY sense probe was used for a negative control, no signal was detected (Figure 7c,f,i) . These results suggest that the ASY gene may play a role in the carcinogenesis of SCLC.
Discussion
In the present study, we report the isolation and characterization of the new gene, ASY. This gene has a very strong apoptosis-inducing tendency especially in malignant cancer cell lines, such as SaOS-2, HT-1080, MeWo and CGL4. Nearly 100% of these cell lines expressing ectopic ASY underwent apoptosis ( Figures  3, 4 and 6) , and stable cell lines expressing ASY could not be obtained. This gene encodes a unique proapoptotic protein which has no homology to other known apoptotic proteins or domains but contains an acidic region, a proline-rich region, two hydrophobic domains, and the ER retrieval motif (Figure 1) . Further, this protein localizes in the ER (Figure 5 ), which no other known apoptotic proteins do. These observations indicate that the ASY gene is a new type of apoptosis-inducing gene. Figure 5 Localization of ASY protein in the ER. (a) CGL1(Bcl-2) cells were transfected with a FLAG-tagged ASY expression vector and ®xed with 4% paraformaldehyde 16 h later. The FLAG-tagged ASY protein was detected with a monoclonal anti-FLAG antibody and an Alexa 488-labeled anti-mouse IgG (Molecular Probes). (b) CGL1(Bcl-2) cells transfected with a FLAG-tagged ASY were fractionated into mitochondrial, microsomal, and cytosolic components, and these components were subjected to Western blot analysis using an anti-FLAG antibody Recently, a novel gene, Nogo, has been reported by three groups (Chen et al., 2000; GrandPre et al., 2000; Prinjha et al., 2000) . It codes for three splice variants, Nogo-A, B and C. The Nogo-A protein is expressed predominantly in myelinating cells from the central nervous system, oligodendrocytes and inhibits neurite outgrowth from cultured neurons when added to media, suggesting that it may be an inhibitor of regeneration of damaged axons in the central nervous system. Interestingly, the ASY protein is identical to the Nogo-B. Although whether or not the Nogo-B protein also has the same inhibitory activity as the Nogo-A protein or which region of the Nogo protein is functional is still indistinct, these reports may not be inconsistent with our results described in this paper. As the ASY mRNA was expressed ubiquitously (Figure 2) , it must have a dierent activity in dierent tissues from that to inhibit axonal regeneration in the central nervous system. The present study may contribute to understanding the whole characters of the ASY/Nogo protein.
The mechanism of ASY-induced apoptosis has not yet been elucidated. Using CGL1 cell lines that express the anti-apoptotic gene Bcl-2 or crmA, we examined whether or not the ASY protein mediates Bcl-2 or Fas pathways for apoptosis. Bcl-2 blocks apoptosis by binding to proapoptotic Bcl-2 family proteins or by other mechanisms (Kroemer, 1997) , and crmA inhibits the activity of Fas pathway-speci®c caspases, such as caspase-8 (Zhou et al., 1997) . When these cell lines were transfected with the GFP-tagged ASY expression vector, Bcl-2, but not crmA, seemed to block ASYinduced apoptosis to some extent. However, probably due to the strong apoptosis-inducing activity of ASY, the blocking activity was not apparent enough to unambiguously answer this question at present.
Because the ASY protein targets the ER, it must modulate certain ER functions. One ER function is to sequester Ca 2+ from the cytoplasm. If the ASY protein induces an eux of Ca 2+ ions from the ER, the cytoplasmic Ca 2+ -dependent phosphatase, calcineurin, will be activated and dephosphorylate Bad, which leads to apoptosis (Wang et al., 1999) . However, apoptosis was eciently induced, even when transfection with the ASY gene was performed in the presence of a calcineurin inhibitor, cyclosporin A (data not shown). This suggests that ASY may not aect intracellular Ca 2+ ion control. The ER is also associated with other apoptotic responses. A mechanism for sensing cellular physiological changes may exist in the ER, and apoptosis is induced by various ER stresses, such as Ca 2+ depletion, inhibition of N-glycosylation and protein transport (Urano et al., 2000) . A recent paper has reported that these ER stresses activated caspase-12 localized in the ER to induce apoptosis (Nakagawa et al., 2000) . However, further studies are needed to clarify the mechanism of ASY-induced apoptosis.
In this study, we also report the interesting observation that ASY preferentially induced apoptosis in cancer cells (Figures 3 and 4) . It is dicult to account for this phenomenon de®nitively, but a similar preference has also been observed in other cases. Tumor suppressor genes Rb and p53, for example, induce growth arrest or apoptosis more eciently in cells containing defects in these proteins than in those with wild-type proteins (Banerjee et al., 1992; Johnson et al., 1991) . If these examples also apply to the present case, it means that many cancer cells must have mutations in the ASY gene or other genes on the ASY-involved apoptotic pathway. In accordance with this hypothesis, ®ve SCLCs ceased to express ASY mRNA (Figure 7) . Although it is very important to clarify the mechanism of downregulation, we could not analyse the ASY gene in SCLC cells in detail because ASY-negative SCLC frozen tissues were unavailable. We need to examine pairs of formalin-®xed and un®xed frozen tissues from other cases of SCLC.
The ASY gene may be very useful for clinical applications. This gene induced apoptotic cell death eciently and preferentially in cancer cells as described above. In preliminary experiments, this gene also induced apoptosis eciently in cancer cell lines other than those used in this study, such as a cervical cancer cell line, C33A, a pancreatic cancer cell line, MIAPaCa-2, and a gastric cancer cell line, AZ521. This indicates that this gene is eective for many types of cancer cells. These results also suggest that the ASY gene may be suitable in gene therapy treatments for cancer. We hope to develop systems for gene therapy using the ASY gene.
Materials and methods
Cells
Cells were cultured in Dulbecco's modi®ed essential medium supplemented with 10% fetal bovine serum. CGL1 and CGL4 are non-tumorigenic and tumorigenic cell lines derived from a hybrid between a human cervical cancer cell line, HeLa and diploid human ®broblasts, respectively (Stanbridge et al., 1982) . HFI is an SV40-immortalized, non-malignant, human ®broblast cell line (Oka et al., 1999) . SaOS-2 (osteosarcoma), HT1080 (®brosarcoma) and MeWo (melanoma) are malignant tumorigenic human cancer cell lines.
Cloning of the ASY cDNA
The tumorigenic cell line, CGL4, was transfected with an EBO-based cDNA expression library prepared from normal human ®broblasts, and then cultured for 2 days in a serumfree medium containing FdU and Ara C. After cultivation was continued in a normal medium, surviving cell clones were isolated. From these cell clones, cDNA could easily be recovered by simple centrifugation, because EBO-based cDNA exists in an extrachromosomal state (Margolskee et al., 1988) . One of the recovered cDNA clones, though incomplete, exhibited some inhibitory activity on colony formation when retransfected. We isolated an almost full sized cDNA clone from a pcD2-based human ®broblast cDNA library and used it in this study.
Northern blot hybridization
Membrane blots with the RNA of various human tissues (Clontech) were hybridized overnight at 428C with 32 P-labeled ASY cDNA probes in 50% formamide, 56SSC (SSC: 0.15 M NaCl and 0.015 M sodium citrate), 0.1% bovine serum albumin, 0.1% Ficoll, 0.1% polyvinylpyrrolidone, 1% SDS, 50 mg/ml salmon sperm DNA and 10% dextran sulfate. They were then washed with 0.16SSC at 558C and autoradiographed.
Transfection
Transfection was carried out using Lipofectamine Plus reagent (Life Technologies) according to the manufacturer's protocol.
Assays for detection of apoptosis
A TUNEL assay, an annexin V-binding assay, and an assay for caspase-3 activity were performed by using an Apotag in situ apoptosis detection kit (Oncor), an ANNEXIN V FITC Kit (Immunotech), and an ApoAlert CPP32¯uorescent assay kit (Clontech), respectively, according to the manufacturers' protocols.
Immunofluorescence staining
Cells were ®xed with 4% paraformaldehyde for 10 min, permeabilized with 0.1% Triton X-100 for 5 min, and incubated successively with a primary monoclonal antibody for 1 h and with a secondary¯uorescence-labeled anti-mouse IgG for 30 min.
Subcellular fractionation
Cells were washed with phosphate-buered saline, scraped o of dishes with a scraper, and collected by centrifugation. The cells were re-suspended in 0.25 M sucrose, 5 mM Tris-HCl (pH 7.4), 100 ng/ml PMSF and 0.25 TIU/ml aprotinin, homogenized by 10 strokes in a Dounce homogenizer, and intact cells and nuclei were removed by centrifugation at 1000 g for 7 min. The cleared lysate was then centrifuged at 8000 g for 10 min to obtain pellets of mitochondria (mitochondria fraction). The supernatant was further centrifuged at 100 000 g for 60 min to separate pellets of microsomes (microsome fraction) from soluble proteins (cytosol fraction).
Western blot analysis
Cell lysates were applied to 5 ± 20% SDS-polyacrylamide gel at 100 V for 2 h, and electroblotted onto a polyvinylidene di¯uoride membrane at 50 V for 2 h. The membrane was incubated successively with a monoclonal antibody and a horseradish peroxidase-conjugated anti-mouse IgG (Amersham). Protein bands were detected using an ECL reagent (Amersham) mRNA in situ hybridization mRNA in situ hybridization was performed on formalin-®xed paran sections as described previously (Shimakage et al., 1997) . Brie¯y, the deparanized sections were hybridized with a digoxigenin-labeled anti-sense or sense riboprobe of the ASY cDNA at 378C for 48 h and incubated with alkaline phosphatase-conjugated anti-digoxigenin antibody at room temperature for 2 h. Signals were visualized by incubation with nitroblue tetrazolium and X-phosphate at 378C for 2 h.
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